KRISHGEN BioSystems

OUR REAGENTS, YOUR RESEARCH

NEUROSCIENCE ELISA

A range of specific and sensitive assays to measure and monitor popular targets for neuro-degenerative diseases and other neuroscience research across 10+ species.

KRISHGEN BioSystems

Learn more about our products:

www.krishgen.biz
kbiinfo@krishgen.com

ĐENIS
MAISON FONDÉE EN 1862

Neuroscience research holds paramount importance in deciphering the intricate workings of the human brain. Through rigorous investigation and innovative methodologies, scientists have made significant progress in understanding the complex neural mechanisms underlying cognition, behavior, and various neurological disorders. It is rapidly advancing, propelled by ongoing endeavors to understand neural circuitry, develop brain-machine interfaces, and explore avenues for brain repair. Neurodegenerative diseases, characterized by the progressive degeneration of neurons in the brain, pose significant challenges to global health, affecting millions of individuals worldwide. While several specific therapeutic strategies are being explored and investigated for treatment, neurological disease markers generally have proven elusive for conclusive results.

Whether it's Alzheimer's or Parkinson's, or more complex spectrum disorders like autism or other auto-immune neural diseases like MS, understanding neuroinflammation and neurological biomarkers might allow for earlier detection and controlling symptoms.

Krishgen's offers a range of highly validated neuro-marker and mAb drug ELISA to support and accelerate research on the neuroscience and neuro-degenerative diseases. Each kit is put through rigorous testing to ensure high precision, accuracy, sensitivity, and specificity. You can be confident that you will obtain reproducible results, day-after-day, and lot-after-lot.

mAb Drugs for Neurodegenerative Diseases

Monoclonal antibodies are engineered immune system proteins that bind specifically to disease-associated targets, such as misfolded proteins or toxic aggregates, facilitating their clearance or neutralization. Popular targets for mAb drugs are Tau, Amyloid-beta and Alpha-synuclein. As of 2023, only a handful of mAb drugs have been approved for therapy, with several others in on-going clinical trials.

Drug Name	Target	Indication	mAB ELISA	Target ELISA
Aducanumab	Beta-amyloid	Alzheimer's Disease	coming soon	KBH20020
lecanemab	Beta-amyloid		coming soon	KBH20021
Natalizumab	Alpha-4 integrin	Multiple Sclerosis (MS)	KBI1020	KBH3900
Ocrelizumab	CD20		KBI1512	KBH3877
Alemtuzumab	CD52		KBI1012	KBH4169

ELISA for Popular Targets in Neurodegenerative Disease Research

Target	Human ELISA	Mouse ELISA	Rat ELISA	Other Species
Tau	KBH1333	KLM1564	KLR1191	General
	KBH6248			
Serum Amyloid A	KBH1225	KLM0372	KLR0679	Rabbit, Porcine, Bovine, Goat, Canine, Chicken, Sheep, Horse
Amyloid Beta 40	KBH20020	KLM0305	KLR0092	
Amyloid Beta 42	KBH20021	KLM9012	KLR0093	

Target	ELISA Available		
	Human	**Mouse**	**Rat**
Acetylcholinesterase	KBH0817		KLR0724
ADAMDEC1	KBH4904		
ADM	KBH1024		KLR0547
AGRN	KBH0413		KLR3459
AGRP	KBH1478	KLM1825	KLR1274
ALDH1L1	KBH20111		
Alpha-1-Microglobulin	KBH20011	KLM5018	KLR1115
Alpha-2-Microglobulin	KBH4926	KLM5019	KLR1365
Amylin	KBH0016	KLM0295	KLR0718
ANNA1	KBH20142		
APOA1	KBH1535	KLM2012	KLR0743
APOA1BP	KBH4971		
APOE	KBH20167	KLM5153	KLR3511
AQP-4	KBH0616	KLM0510	KLR0568
Ascl1	KBH3598		
AVP	KBH1312		
BACE1	KBH0802	KLM1559	KLR1225
BDNF	KBH1302	KLM0013	KLR0476
Beta 2-microglobulin	KBH235010	KLM5207	KLR3535
Beta 2TF	KBH3370		
Beta III Tubulin	KBH6334		
CALB1	KBH20331	KLM5281	
CC16	KBH0073	KLM0623	KLR0424
CD11b	KBH20386		KLR3605
CD40	KBH3153	KLM1207	KLR1745
CD45	KBH5054	KLM5327	KLR1912
CD68	KBH4776	KLM2231	KLR1384
CDNF	KBH2889	KLM1552	KLR0865
CFHR1	KBH4211		
Choline acetyltransferase	KBH5039		KLR0725
Chromogranin A	KBH1730	KLM5357	KLR0557
CIRBP	KBH5066	KLM1951	KLR1332
CLASP2	KBH5053		
CNTF	KB1022	KLM0327	KLR0358
CRHBP	KBH20569		KLR3686
CTGF	KB1026	KLM0688	KLR0356
CX3CR1	KBH0296	KLM5436	KLR1934
CXCL10	KBH3800	KLM5438	
Cystatin B	KBH2809		KLR3698
Dopamine transporter	KBH4006		KLR0222
Doublecortin	KBH4190	KLM1744	KLR3743

Target	ELISA Available		
	Human	**Mouse**	**Rat**
E-cadherin		KLM0008	KLR0057
EAAT1	KBH20753	KLM5493	
EAAT2	KBH20754	KLM5494	KLR3767
ENO1	KBH0960		
ENO1/MBPB1/MPB1	KBH4933		
eNOS	KBH0908	KLM0387	KLR0465
FOXA2	KBH20920		
FOXO3	KBH0626	KLM0997	
G-CSF	KBH0121	KLM0641	KLR0428
GAD65	KBH3504		
GAL	KBH1332 KBH20958	KLM2084	KLR0246
Galanin	KBH1332	KLM2084	KLR0246
GALP	KBH4655		
Gamma-Secretase	KBH4388		
GAP43	KBH1853	KLM1027	
GAP43 / Neuromodulin	KBH20964		
GDNF	KBH0122	KLM0677	KLR0351
GFAP	KBH2094	KLM0367	KLR0538
GFAP	KBH2094	KLM0367	KLR0538
GIRK2	KBH1100		
Glutaminase	KBH21008	KLM5635	KLR2016
Glutamine synthetase	KBH4569	KLM5661	KLR3924
GRIN2B	KBH4453		KLR1204
GRO alpha/MGSA	KBH0167		
GRP	KBH1364		
Haptoglobin	KBH1117	KLM5742	KLR0357
HES1	KBH6287	KLM2588	KLR3952
HNP1-3	KBH0341		
HSP70	KBH1813	KLM1752	KLR0522
HSP90 alpha	KBH3002	KLM0869	KLR0874
HTRA2	KBH2747		
HTT	KBH5437	KLM5757	KLR2010
Huntingtin	KBH2748		KLR2010
Iba1	KBH21227	KLM5761	KLR3988
IDE	KBH5471	KLM0489	KLR1387
iNOS	KBH21778		
LGI1	KBH5562		
LGI3	KBH5564	KLM2207	
LMX1B	KBH21458		
LRP1	KBH2298	KLM0837	KLR0209
LZM	KBH0325	KLM0202	KLR4082

ELISA for other areas neuroscience research (continued)

Target	ELISA Available			Target	ELISA Available		
	Human	**Mouse**	**Rat**		**Human**	**Mouse**	**Rat**
MAP2	KBH1309	KLM5891	KLR1772	NPFFR2	KBH21787		
MAPT	KBH21528	KLM1564	KLR1191	NPTX2	KBH4709	KLM6020	KLR4183
MBP	KBH5709	KLM0548	KLR2161	NPY	KBH1285c	KLM0704	KLR0540
MFN1				NPY1R	KBH21793	KLM6021	KLR4184
MLCK	KBH0944	KLM5931	KLR0310	NPY2R	KBH21794	KLM6022	KLR4185
MMP9	KBH0936	KLM0277	KLR0321	Nrf2	KBH3244	KLM1367	KLR1083
MOG	KBH3069	KLM1124	KLR0859	NRG2	KBH5751		KLR4191
MPZ	KBH3720		KLR4130	NRG4	KBH3931	KLM2292	
N-cadherin		KLM5982		NRN1	KBH5752		KLR2172
NCAM-L1	KBH0276			NRP2	KBH5764		KLR2180
NCAM1	KBH3986			NRTN	KBH5770		
NCAM1	KBH3986			NT	KBH1318	KLM6031	KLR4194
NCAM2	KBH21713			NTF4	KBH5768	KLM0085	KLR0544
NDNF	KBH21723	KLM5986		Ntn1	KBH1277	KLM1802	KLR0772
NE	KBH0890	KLM0025	KLR0761	NTS		KLM2299	KLR1555
NEFH	KBH3136	KLM1168	KLR0926	occludin	KBH3658	KLM2611	KLR2185
NEFL	KBH4645	KLM5989	KLR1747	Olig 1	KBH0695		
NEO1	KBH2388			Olig 2	KBH21851		
Neprilysin (CD10)	KBH3564			OPRM1	KBH3534		KLR1559
Nesfatin-1	KBH3063	KLM1704	KLR0878	Optineurin	KBH3579		
Nestin	KBH3341	KLM1451	KLR1174	Orexin A	KBH1296	KLM0444	KLR0105
NeuroD1	KBH2920			P2RX7	KBH5825		
Neurogranin	KBH3883			P75NTR	KBH4534		
Neurokinin 1 Receptor		KLM2020		PARK2	KBH4852		
Neurokinin A	KBH1930	KLM6003	KLR2340	PARK7	KBH4179	KLM2382	KLR2216
Neurokinin B	KBH3086		KLR4172	PAX6	KBH4713		KLR4222
Neuromedin-K receptor	KBH22556			PDGF receptor alpha	KBH0200	KLM0638	KLR0694
Neuromedin-S / NMS	KBH21773			PEDF	KBH1634	KLM0615	KLR0535
Neuropathy target esterase	KBH22077		KLR4199	PENK	KBH2341	KLM2362	KLR4246
Neuropeptide S	KBH4784	KLM2298	KLR2177	PLXNB1	KBH2635		
Neurotrophin-3				pMAPT /pTAU	KBH5874	klm1799	
NF-L	KBH4624			PMP2	KBH6657	KLM6144	KLR4291
NGB	KBH1314	KLM6002	KLR0474	pNF-H	KBH3879		
NGF	KBH2102	KLM0081	KLR0539	Presenilin 1	KBH5908		
Nicalin				Presenilin 2	KBH0980		
Nicastrin				Prion protein PrP			
NINJ1	KBH5776			PRL	KBH0999	KLM6175	KLR4314
NLGN3	KBH21767		KLR2338	Profilin1	KBH5920		
NMU	KBH3368	KLM1455	KLR1178	PROK2	KBH5929	KLM2365	
nNOS	KBH5761			proNGF	KBH5936		
Notch 1	KBH3218		KLR1020	PTHrP	KBH1018	KLM2329	KLR0334
Notch 3	KBH3263	KLM1394		PYY	KBH22203	KLM2332	KLR2205

Target	ELISA Available			Target	ELISA Available		
	Human	**Mouse**	**Rat**		**Human**	**Mouse**	**Rat**
REG3G	KBH22243	KLM2422	KLR4351	Synaptophysin	KBH4497	KLM2581	KLR1496
RELN	KBH6072	KLM2421	KLR2232	Synaptotagmin 11	KBH2573		
S100	KBH1289	KLM0190	KLR0076	Synuclein Gamma	KBH3267	KLM1396	KLR1974
S100 beta	KBH3669	KLM1491	KLR0075	SYP	KBH4497	KLM2581	KLR1496
S100A12	KBH3074			TARDBP	KBH0333		
S100A4	KBH6000	KLM2394	KLR1341	TARDBP/TDP43	KBH0333		
SAA3	KBH1256	KLM2465		TGF-alpha	KBH0136	KLM0238	KLR0777
SAA4	KBH6165	KLM6267		TGM2	KBH0958		
sAPP Alpha	KBH3278			TH	KBH0720	KLM1543	KLR1316
SCUBE1	KBH3142		KLR0948	TMEM119	KBH6313		
SDC1	KBH3344	KLM2501	KLR2272	TN-C	KBH4725		
SDC2	KBH6242	KLM2502		TNC	KBH1414		KLR0750
SDC4	KBH4449	KLM2500	KLR1588	Tpa	KBH3707		
Senataxin				TPP1	KBH2520		
Septin5	KBH6137			TREM2	KBH4189	KLM2525	
Serotonin transporter	KBH3595		KLR1254	TUBB3	KBH6334		
SERPINE2	KBH5327			TWSG1	KBH2424		
SMN1	KBH22461	KLM6334		Tyrosine Hydroxylase	KBH0720	KLM1543	KLR1316
SMPDL3B	KBH4893			UCHL1	KBH2328	KLM0905	KLR2312
SNCa	KBH1313	KLM1401	KLR1111	Versican/PG-M/PG-350	KBH1909		
SOD1	KBH4502	KLM2608		Vesicular acetylcholine transporter	KBH22797		KLR4409
SOX10	KBH6662						
SOX2	KBH6291		KLR4443	VGF	KBH4056	KLM6483	KLR2322
SP1	KBH6294			VGLUT1		KLM6484	
Stathmin 1	KBH6487			Vimentin	KBH1673	KLM6485	KLR2323
suPAR	KBH3759			YBX1	KBH5799		

Krishgen offers the above ELISA markers in various other species including porcine, bovine, horse, monkey etc. Get in touch with our team at info@krishgen.com for more information.

Future trends in neuroscience and neuro-degeneration research:

In addition to currently approved mAb drugs, several other innovative therapeutic approaches are also being explored to combat neurodegenerative diseases. Some noteworthy areas include:

BiTE (Bispecific T-cell Engager) antibodies: Novel antibodies that can simultaneously bind to both disease-causing proteins and immune cells, facilitating clearance of toxic protein aggregates. BiTE antibody drugs targeted to alpha-synuclein are currently in preclinical development for Parkinson's disease.

Small molecule inhibitors: In addition to mAbs, small molecule inhibitors are being investigated to target specific disease-related pathways and proteins implicated in neuro-degeneration. For example, small molecules that inhibit the enzyme responsible for producing Aβ have shown encouraging results in preclinical studies. Beta-secretase (BACE) inhibitors, specifically, that target the enzyme responsible for producing Aβ precursor protein (APP), with several inhibitors are currently in development for Alzheimer's disease.

Neuroprotective peptides: Peptides derived from natural sources or designed de novo have demonstrated neuroprotective properties in preclinical studies. These peptides can inhibit toxic protein aggregation, promote neuronal survival, and enhance brain repair processes, offering potential therapeutic avenues for neurodegenerative diseases.

DIDN'T FIND WHAT YOU'RE LOOKING FOR?

Krishgen manufactures 20,000+ ELISA across more than 10 species. Talk to our technical team to find the right product for you at **info@krishgen.com**.

Or, get in touch with us to custom develop your assay. Our custom services can help designing and producing sensitive, validated kits for your target(s) of interest.

For more information, please reach out to us at **services@krishgen.com**.

KRISHGEN *BioSystems*

OUR REAGENTS, YOUR RESEARCH

ĐENIS
MAISON FONDÉE EN 1862

DENISファーマ株式会社

TEL : 03-5510-2932 / e-mail : info@denispharma.jp
東京都千代田区霞が関三丁目6番7号
https://research.sceti.co.jp/